Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelvion in Severe Hemophilia B Patients Switching From Previous Factor IX Treatment
NCT04108260Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Apr 2020
- Primary completion
- Nov 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT04108260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108260.